Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort

Increased dolutegravir peak concentrations in people living with HIV aged 60 and over and analysis of sleep quality and cognition

(2018) Emilie R Elliot et al.   CLINICAL INFECTIOUS DISEASES

Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals

(2018) Andrew M. Hill et al.   Current Opinion in HIV and AIDS

Morning dosing for dolutegravir-related insomnia and sleep disorders

(2017) AF Capetti et al.   HIV MEDICINE

Psychiatric Symptoms in Patients Receiving Dolutegravir

(2017) Anna Fettiplace et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Tolerability of integrase inhibitors in a real-life setting

(2017) Judit Peñafiel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

(2017) Catherine Orrell et al.   Lancet HIV

Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2017)

(2017)   ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA

Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice

(2016) Mark G.J. de Boer et al.   AIDS

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection

(2016) David Nicolás et al.   CLINICAL INFECTIOUS DISEASES

Neuropsychiatric Effects of HIV Antiviral Medications

(2016) Glenn J. Treisman et al.   DRUG SAFETY

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

(2016) C Hoffmann et al.   HIV MEDICINE

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2016) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study

(2016) Kathleen Squires et al.   Lancet HIV

Psychiatric side effects of non-psychiatric drugs

(2014) Carl Holvey et al.   BRITISH JOURNAL OF HOSPITAL MEDICINE

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

(2014) A. Castagna et al.   JOURNAL OF INFECTIOUS DISEASES

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

(2013) Mackenzie L. Cottrell et al.   CLINICAL PHARMACOKINETICS

Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs

(2013) Michael S. Abers et al.   CNS DRUGS

Dolutegravir: First Global Approval

(2013) Anita D. Ballantyne et al.   DRUGS

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lack of Interaction Between the HIV Integrase Inhibitor S/GSK1349572 and Tenofovir in Healthy Subjects

(2010) Ivy Song et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study

(2009) R Giuntini et al.   HIV MEDICINE

Neuropsychiatric Aspects of Infectious Diseases

(2008) Stephen J. Ferrando et al.   CRITICAL CARE CLINICS